VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
MEDS
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
MEDSDataMEDS AI, Inc.
$1.34$5M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksMEDSBalance Sheet

DataMEDS AI, Inc. (MEDS) Balance Sheet

3Y historyFree accessUpdated daily

Negative equity of -$1.7M against $38.6M of total liabilities and a current ratio of 0.14 indicates that the capital structure is highly leveraged and liquidity is thin relative to obligations.

Income StatementBalance SheetCash FlowRatios

MEDS Balance Sheet

Annual statement

MEDS Balance Sheet

DataMEDS AI, Inc. (MEDS) balance sheet — 3-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23
Total Current Assets5.22M2.82M15.17M338.36K
Cash & Short-Term Investments476.6K42.57K1.03M1.36K
Cash Only476.6K42.57K1.03M1.36K
Short-Term Investments0000
Accounts Receivable3.13M1.14M3.75M337K
Days Sales Outstanding76.7517.7975.42-
Inventory1.44M1.64M9.52M0
Days Inventory Outstanding32.1818.15212.35-
Other Current Assets00875.39K0
Total Non-Current Assets33.51M27.64M42.16M0
Property, Plant & Equipment1.91M1.2M1.92M0
Fixed Asset Turnover6.08x19.51x9.46x-
Goodwill15.79M14.19M16.22M0
Intangible Assets13.25M10.31M22.36M0
Long-Term Investments35K017.67K0
Other Non-Current Assets2.53M1.94M1.65M0
Total Assets38.73M30.46M57.33M338.36K
Asset Turnover0.23x0.77x0.32x-
Asset Growth %-161.18%-46.87%16844.08%-
Total Current Liabilities37.91M29.78M38.05M2.89M
Accounts Payable13.06M11.69M6.33M1.04M
Days Payables Outstanding252.06129.4141.31-
Short-Term Debt18.06M11.07M12.04M350K
Deferred Revenue (Current)514.23K488.23K245.76K0
Other Current Liabilities5.53M4.59M3.11M950K
Current Ratio0.14x0.09x0.40x0.12x
Quick Ratio0.10x0.04x0.15x0.12x
Cash Conversion Cycle-143.13-93.47146.46-
Total Non-Current Liabilities648.72K13.13M12.55M350K
Long-Term Debt100K13.13M11.46M350K
Capital Lease Obligations548.72K01.1M0
Deferred Tax Liabilities0000
Other Non-Current Liabilities0000
Total Liabilities38.56M42.91M50.6M3.24M
Total Debt19.94M24.77M25.11M700K
Net Debt19.47M24.73M24.08M698.64K
Debt / Equity116.15x-3.73x-
Debt / EBITDA-0.72x---
Net Debt / EBITDA-0.70x---
Interest Coverage-4.32x-21.11x-7.25x-191.01x
Total Equity171.69K-12.45M6.73M-2.9M
Equity Growth %-3073.17%-284.84%332.19%-
Book Value per Share0.04-8.776.48-3.24
Total Shareholders' Equity-1.7M-12.45M6.73M-2.9M
Common Stock47310.13K5.11K4.47K
Retained Earnings-126.55M-111.03M-9.76M-2.9M
Treasury Stock0000
Accumulated OCI0000
Minority Interest1.87M000

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Negative equity and persistent cash burn

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Equity Deficit Deepens Despite Asset Growth

Based on reported figures, DataMEDS AI moved from $10.0M of equity in 2024Q3 to a deficit of -$1.7M in 2026Q3, while accumulated deficit widened from -$5.4M to -$126.5M over the same period.

The erosion of equity is driven by the accumulated deficit rather than by any single discrete event, which suggests losses have consistently outpaced capital retained in the business. Total assets rose to $38.7M in 2026Q3 from $30.1M in 2026Q1, but liabilities grew at a similar pace, so the balance sheet expansion appears to be financed by obligations rather than by owner capital. Investors should monitor whether the balance sheet stabilizes or continues to weaken, since a negative equity position limits the company's cushion against further losses.

Leverage Rises as Equity Turns Negative

According to the reported statements, total debt of $19.9M in 2026Q3 against a negative equity base produces a D/E ratio of 116.15, a figure that reflects the depleted equity cushion rather than a modest debt load.

Debt declined from $32.6M in 2026Q2 to $19.9M in 2026Q3, which may indicate partial repayment or reclassification, though the reported figures do not disclose the mechanism. The D/E ratio is extreme in part because it is computed against near-zero equity, so it overstates leverage in a relative sense while still signaling that creditors hold a dominant claim on the asset base. Refinancing terms and maturity schedules are not provided in the supplied data, so the ability to service this debt warrants further investigation.

Asset Base Dominated by Non-Productive Holdings

Based on EDBL-style reported figures, goodwill of $15.8M and net PPE of $1.9M in 2026Q3 together account for roughly 45% of total assets of $38.7M, pointing to an asset base weighted toward intangibles.

The business appears asset-light in physical terms, with PPE declining from $2.1M in 2024Q2 to $1.9M in 2026Q3, which suggests limited reinvestment in productive capacity. Goodwill has held near $14 to $16M across the period, so its recoverability is a material judgment, and an impairment would further reduce an already negative equity balance. The composition suggests that reported asset values may depend heavily on acquisition accounting rather than on tangible earning power.

Thin Liquidity Buffer Against Obligations

As reported in financial statements, cash of $476.6K against a current ratio of 0.14 in 2026Q3 indicates that current liabilities are many multiples of available liquid resources.

A current ratio of 0.14 means the company holds roughly $0.14 of current assets for each dollar of current obligations, a position that is structurally fragile regardless of the underlying business outlook. Cash has fluctuated between roughly $42K and $4.2M across the ten quarters, offering little durable buffer against operating shortfalls. The data does not disclose committed credit facilities, so any external funding access is unverified and should not be assumed.

Headline Assets Mask Negative Net Worth

Based on reported figures, total assets of $38.7M in 2026Q3 appear substantial in isolation, yet they are fully offset by liabilities of $38.6M, leaving equity negative and the asset base largely committed to creditors.

The most misleading read would be to treat the $38.7M asset total as evidence of scale or stability, since the entire asset base is matched by claims that exceed it in aggregate. Goodwill and other intangibles of roughly $15.8M carry impairment risk that, if recognized, would deepen the equity deficit without any change in cash. This analysis is inferential from the reported figures and does not account for contingent liabilities, lease obligations, or other items not disclosed in the supplied data.

MEDS — Frequently Asked Questions

Quick answers to the most common questions about buying MEDS stock.

What are the total assets of DataMEDS AI, Inc. (MEDS)?

As of 2025, DataMEDS AI, Inc. (MEDS) had total assets of $30.5M including $2.8M in current assets.

How much debt does DataMEDS AI, Inc. (MEDS) have?

DataMEDS AI, Inc. (MEDS) carries total debt of $24.8M, offset by $0.0M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of DataMEDS AI, Inc.?

DataMEDS AI, Inc. (MEDS) has total shareholders' equity (book value) of $-12.4M ($-8.77 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is DataMEDS AI, Inc.'s current ratio and liquidity?

DataMEDS AI, Inc. (MEDS) reported a current ratio of 0.09x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.